A detailed history of Herbst Group, LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Herbst Group, LLC holds 25,000 shares of AUTL stock, worth $83,500. This represents 0.06% of its overall portfolio holdings.

Number of Shares
25,000
Holding current value
$83,500
% of portfolio
0.06%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$3.38 - $4.69 $84,500 - $117,250
25,000 New
25,000 $90,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $304M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Herbst Group, LLC Portfolio

Follow Herbst Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Herbst Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Herbst Group, LLC with notifications on news.